ASCO GU 2019 - Results from #40

Viewing 41-60 of 154 articles

ASCO GU 2019: Malignant Pheochromocytoma: Comprehensive Genomic Profiling Study

ASCO GU 2019: Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer

ASCO GU 2019: Prevention of Symptomatic Skeletal Events with Denosumab: REDUSE Trial

ASCO GU 2019: Accelerated versus Standard BEP Chemotherapy for Adult and Pediatric Male and Female Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors

ASCO GU 2019: The PRIMETEST Trial: Interim Analysis of a Phase II Trial for Primary Retroperitoneal Lymph Node Dissection (RPLND) in Stage II A/B Seminoma Patients without Adjuvant Treatment

ASCO GU 2019: Enzalutamide and ADT with Salvage Radiation in Men with High-Risk PSA Recurrent Prostate Cancer: The STREAM trial

ASCO GU 2019: Patients with Previously Treated Metastatic Urothelial Cancer Treated with Sacituzumab Govitecan (IMMU-132)

ASCO GU 2019: Ramucirumab Exposure-Response Relationship in RANGE: Trial in Advanced Platinum-Refractory Urothelial Carcinoma

ASCO GU 2019: Non-Clear Cell Renal Cell Carcinoma: Jumping on the Immunotherapy Bandwagon

ASCO GU 2019: Risk Stratification After Resection of Localized Disease: Which Model to Use, and Why?

ASCO GU 2019: Pembrolizumab in Muscle-Invasive and Locally Advanced Urothelial Carcinoma - AMBASSADOR versus Observation

ASCO GU 2019: A Phase III, Randomized, Open-label, Multicenter, Global Study of Durvalumab and BCG versus BCG Alone in High-risk, BCG-naïve Non-muscle-invasive Bladder Cancer Patients - POTOMAC

MDxHealth Announces Presentation of Positive Data for SelectMDx and ConfirmMDx in Prostate Cancer Diagnosis

ASCO GU 2019: CB-839, A Glutaminase Inhibitor, in Combination with Cabozantinib in Patients with Clear Cell and Papillary Metastatic Renal Cell Cancer

ASCO GU 2019: Informing the Decision Using Clinical Trial Evidence - Localized Kidney Cancer

ASCO GU 2019: Safety and Efficacy of Nivolumab in Metastatic Renal Cell Carcinoma: Final Analysis from the NIVOREN GETUG AFU 26 Study

ASCO GU 2019: Phase Ib (COSMIC-021) Trial of Cabozantinib in Urothelial Carcinoma or Cabozantinib in Combination with Atezolizumab in patients with Urothelial Carcinoma, Castrate Resistant Prostate Cancer or Renal Cell Carcinoma

ASCO GU 2019: CANTATA: Randomized, International, Double-Blind Study of CB-839 Plus Cabozantinib versus Cabozantinib Plus Placebo in Patients with Metastatic Renal Cell Carcinoma

ASCO GU 2019: First-line Pembrolizumab Monotherapy for Advanced Non-Clear Cell Renal Cell Carcinoma: Results from KEYNOTE-427 Cohort B

ASCO GU 2019: Discussion on: The KEYNOTE-426 Study and the Subgroup Analysis from the JAVELIN Renal 101

1
2
3
4
5
6
7
8